Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors

    Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of
                                  Directors

PR Newswire

LA JOLLA, Calif., June 11, 2013

LA JOLLA, Calif., June 11, 2013 /PRNewswire/ -- Regulus Therapeutics Inc.
(NASDAQ:RGLS), a biopharmaceutical company leading the discovery and
development of innovative medicines targeting microRNAs, announced today that
it has named Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
effective immediately.

Dr. Papadopoulos assumes the role of Chairman of the Board from John
Maraganore, Ph.D., who will remain a member of the Board of Directors. Dr.
Papadopoulos, who has been a member of the Board since 2008, has more than 30
years of experience in the biotechnology and pharmaceutical industries as an
investment banker, board member, company founder and investor. Dr.
Papadopoulos is a Board member of several companies including Biogen Idec,
Inc. and Exelixis, Inc., where he is Chairman.

"Stelios brings together financial savvy, business ingenuity and scientific
creativity," said John Maraganore, Ph.D., member of the Board and President
and CEO of Alnylam Pharmaceuticals, Inc. "I couldn't think of a more
accomplished individual to become Chairman of Regulus' Board."

"Stelios' transition to Chairman of the Board comes at a very exciting time
for Regulus," said Kleanthis G. Xanthopoulos, Ph.D., President and CEO of
Regulus. "We've achieved early success under our 'Road to the Clinic'
strategy with the recent nomination of our first clinical candidate, RG-101
for the treatment of HCV. Stelios' extensive industry knowledge and
experience are perfectly suited to help advance our microRNA candidates into
clinical development and position Regulus for continued success and growth."

"Regulus is a benchmark of innovation focused on harnessing the power of a
transformative class of novel therapeutics and biomarkers based on microRNAs,"
said Stelios Papadopoulos, Ph.D., Chairman of the Board. "I am excited to
help guide our dedicated and talented team as we strive to execute on Regulus'
scientific and strategic goals."

Dr. Papadopoulos retired as Vice Chairman of Cowen and Company, LLC in 2006
after six years with the firm where he was an investment banker focused on the
biotechnology and pharmaceuticals sectors. Prior to joining Cowen in 2000,
Dr. Papadopoulos was an investment banker at PaineWebber Incorporated, most
recently serving as Chairman of PaineWebber Development Corp., a PaineWebber
subsidiary focusing on biotechnology. Prior to that, he held positions in
Equity Research covering the biotechnology industry at Drexel Burnham Lambert
and Donaldson, Lufkin & Jenrette. He is a co-founder and Chairman of the
Board of Directors of Exelixis, Inc., and a member of the Board of Directors
at Biogen Idec, Inc., BG Medicine, Inc. and Joule Unlimited. Additionally,
Dr. Papadopoulos was a co-founder and former Board member of Cellzome, Inc.
(acquired by GSK in 2012) and Anadys Pharmaceuticals, Inc. (acquired by Roche
in 2011).

Before joining Wall Street, he was on the faculty of the Department of Cell
Biology at New York University Medical Center. Dr. Papadopoulos is also
deeply involved in the non-profit sector. He is a co-founder and Chairman of
Fondation Sante, a charitable foundation for scientific and educational
purposes, and serves on the Board of Visitors at Duke University Medical
Center. Dr. Papadopoulos holds a Ph.D. in biophysics and an M.B.A. in
finance, both from New York University.

About Regulus

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading
the discovery and development of innovative medicines targeting microRNAs.
Regulus is leveraging a mature therapeutic platform based on technology that
has been developed over 20 years. Regulus works with a broad network of
academic collaborators and leverages the oligonucleotide drug discovery and
development expertise of its founding companies, Alnylam Pharmaceuticals and
Isis Pharmaceuticals. Regulus is developing RG-101 for the treatment of HCV
and is advancing other microRNA therapeutics toward clinical development in
several areas, including oncology, fibrosis and metabolic diseases. Regulus
has formed strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi
and a research collaboration with Biogen Idec.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements
associated with Regulus' expectations regarding future therapeutic and
commercial potential of Regulus' business plans, technologies and intellectual
property related to microRNA therapeutics being discovered and developed by
Regulus. Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or implied by such
forward-looking statements. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be incorrect. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of various risks
and uncertainties, which include, without limitation, risks associated with
the process of discovering, developing and commercializing drugs that are safe
and effective for use as human therapeutics, and in the endeavor of building a
business around such drugs. These and other risks concerning Regulus'
programs are described in additional detail in Regulus' SEC filings. All
forward-looking statements contained in this press release speak only as of
the date on which they were made. Regulus undertakes no obligation to update
such statements to reflect events that occur or circumstances that exist after
the date on which they were made.

SOURCE Regulus Therapeutics Inc.

Website: http://www.regulusrx.com
Contact: Amy Conrad, Director, Investor Relations and Corporate
Communications, Regulus Therapeutics Inc., 858-202-6300,
aconrad@regulusrx.com; or Media, David Schull, Russo Partners LLC,
212-845-4271, david.schull@russopartnersllc.com
 
Press spacebar to pause and continue. Press esc to stop.